Compare · EDSA vs JNJ
EDSA vs JNJ
Side-by-side comparison of Edesa Biotech Inc. (EDSA) and Johnson & Johnson (JNJ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EDSA and JNJ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $538.04B, about 9044.6x EDSA ($59.5M).
- Over the past year, EDSA is up 237.6% and JNJ is up 43.8% - EDSA leads by 193.8 points.
- EDSA has been more active in the news (19 items in the past 4 weeks vs 11 for JNJ).
- JNJ has more recent analyst coverage (25 ratings vs 1 for EDSA).
- Company
- Edesa Biotech Inc.
- Johnson & Johnson
- Price
- $6.68-8.24%
- $223.50-0.77%
- Market cap
- $59.5M
- $538.04B
- 1M return
- -63.33%
- -2.80%
- 1Y return
- +237.63%
- +43.82%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 19
- 11
- Recent ratings
- 1
- 25
Edesa Biotech Inc.
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 2/Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical cream containing non-steroidal anti-inflammatory compound that is in Phase 2B clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of sPLA2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, a monoclonal antibody candidate. It has a collaboration agreement with NovImmune SA to develop products containing toll-like receptor 4 and chemokine ligand 10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest EDSA
- Chief Executive Officer Nijhawan Pardeep was granted 1,671 shares, increasing direct ownership by 0.23% to 731,134 units (SEC Form 4)
- Director Marshall Patrick was granted 19,000 shares, increasing direct ownership by 36% to 71,666 units (SEC Form 4)
- Director Macdonald Sean Arthur was granted 19,000 shares, increasing direct ownership by 86% to 41,054 units (SEC Form 4)
- Director Chypyha Joan was granted 19,000 shares, increasing direct ownership by 172% to 30,029 units (SEC Form 4)
- Chief Financial Officer Weiler Peter J. was granted 64,609 shares, increasing direct ownership by 99% to 129,609 units (SEC Form 4)
- President Brooks Michael J was granted 64,609 shares, increasing direct ownership by 28% to 291,479 units (SEC Form 4)
- Director Sistilli Carlo was granted 19,000 shares, increasing direct ownership by 62% to 49,417 units (SEC Form 4)
- Director Olson Charles V was granted 19,000 shares, increasing direct ownership by 173% to 30,000 units (SEC Form 4)
- Chief Executive Officer Nijhawan Pardeep was granted 96,913 shares, increasing direct ownership by 15% to 729,463 units (SEC Form 4)
- Director Liu Da David was granted 19,000 shares, increasing direct ownership by 345% to 24,501 units (SEC Form 4)
Latest JNJ
- Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
- RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
- New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma
- FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage
- Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
- SEC Form SD filed by Johnson & Johnson
- SEC Form 13F-HR filed by Johnson & Johnson
- CNS Drug Delivery Technologies Are Reshaping Alzheimer's and Biodefense Research
- Johnson & Johnson upgraded by Leerink Partners with a new price target
- Johnson & Johnson to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference